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أنواع التجلط الوعائي الوريدي الدماغي يف سلطنة عمان
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abstract: Objectives: Cerebral venous thrombosis (CVT) can have varied and life-threatening manifestations. This study 
aimed to examine the spectrum of its clinical presentations and outcomes in a tertiary hospital in Oman. Methods: This 
retrospective study was conducted at the Sultan Qaboos University Hospital, Muscat, Oman, between January 2009 and 
December 2017. The medical records of all patients with CVT were reviewed to determine demographic characteristics, 
clinical features and patient outcomes. Results: A total of 30 patients had CVT. The mean age was 36.8 ± 11 years and the 
male-to-female ratio was 2:3. Common manifestations included headache (83%), altered sensorium (50%), seizures (43%) 
and hemiparesis (33%). Underlying risk factors were present in 16 patients (53%). Computed tomography or magnetic 
resonance imaging of the brain was abnormal in all patients, with indications of infarcts (40%) and major sinus thrombosis 
(100%). There were five cases (20%) of deep CVT. The patients were treated with low-molecular-weight heparin, mannitol 
and anticonvulsants. The majority (77%) had no residual neurological deficits at follow-up. Conclusion: These findings 
indicate that CVT is a relatively uncommon yet treatable disorder in Oman. A high index of suspicion, early diagnosis, 
prompt anticoagulation treatment and critical care may enhance favourable patient outcomes.
Keywords: Venous Thrombosis; Cerebral Thrombosis; Cranial Venous Sinuses; Neurological Manifestations; Patient 
Outcome Assessment; Oman.
امللخ�ص: الهدف: التجلط الوريدي الدماغي له مظاهر متنوعة قد تهدد احلياة. هدفت هذه الدرا�شة اإىل معرفة اأنواع هذه اجللطات واأعرا�شها 
ونتائج عالجها يف ُعمان. الطريقة: اأجريت هذه الدرا�شة الرجعية يف م�شت�شفى جامعة ال�شلطان قابو�ص، م�شقط، عمان، بني يناير 2009 
الدميوغرافية،  الدماغي لتحديد اخل�شائ�ص  الوريدي  الطبية جلميع املر�شى امل�شابني بالتجلط  ال�شجالت  ا�شتعرا�ص  2017. مت  ودي�شمرب 
 ±  11 العمر  الدماغي. كان متو�شط  الوريدي  بالتجلط  30 مري�شا  ا�شيب ما جمموعه  النتائج:  للجلطات ونتائجها.  ال�رسيرية  والأعرا�ص 
36.8 �شنة وكانت ن�شبة الذكور اإىل الإناث 2:3. و�شملت الأعرا�ص الكلينيكية ال�شائعة ال�شداع )%83(، وتغري يف حوا�ص املري�ص )50%(، 
والت�شنجات )%43( و وال�شعف الن�شفي )%33(. كانت عوامل اخلطورة الأ�شا�شية موجودة يف 16 مري�شا )%53(. كان نتائج الت�شوير بالرنني 
املغناطي�شي للدماغ غري طبيعيه يف جميع املر�شى، مع وجود موؤ�رسات على جلطة دماغية يف )%40( وجتلط الأوردة الدماغية الرئي�شية يف 
)%100( من احلالت. كانت هناك خم�ص حالت )%20( من التجلط الوريدي الدماغي العميق. مت عالج جميع املر�شى بالهيبارين منخف�ص 
الوزن اجلزيئي، مع  املانيتول اأو م�شادات الت�شنجات ال�رسعية. ظهر اأن غالبية املر�شى )%77( لي�ص لديهم اأي خلل اأوعجز ع�شبي عند 
املتابعة. اخلال�صة: ت�شري هذه النتائج اإىل اأن التجلط الوريدي الدماغي هو ا�شطراب غري �شائع ن�شبيا يف عمان وممكن عالجه بنجاح. اإن 
وجود قدرة عالية لتوقع املر�ص يعزز من فر�ص الت�شخي�ص املبكر وبداأ العالج الفوري مب�شادات التجلط والرعاية املركزة قد يعزز من 
النتائج الإيجابية ل�شفاء املري�ص.
الكلمات املفتاحية: التجلط الوريدي؛ اجللطة الدماغية؛ اجليوب الوريدية الدماغية؛ الأعرا�ص الع�شبية؛ تقييم نتائج املر�شى؛ عمان.
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Advances in Knowledge
- This study reports the spectrum of cerebral venous thrombosis (CVT) in a tertiary hospital in Oman. 
- The approximate prevalence of CVT in the hospital-based cohort was 3%. The CVT survivors had a relatively low incidence of residual 
neurological deficits (14.8%).
Application to Patient Care
- This study emphasises the need for greater awareness of the wide range of clinical manifestations of CVT and highlights the use of 
imaging to ensure the prompt diagnosis of this condition. 
doi: 10.18295/squmj.2018.18.03.011
Cerebral venous thrombosis (cvt)—also known as cerebral sinovenous thrombosis or dural sinus thrombosis—constitutes approx-
imately 0.5% of all stroke syndromes.1 The diverse manif- 
estations of CVT can cause difficulties in diagnosis. 
Moreover, the disease is potentially dangerous, with a 
large proportion of patients experiencing raised intra-
cranial pressure (ICP), focal infarcts and intracerebral 
haemorrhage.1 Due to advances in the diagnostic sensit- 
ivity of imaging methods and the overall quality of 
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management, CVT-related mortality has decreased 
from >30% in 1960 to 5–15% in recent years.2 This study 
aimed to examine the spectrum of CVT in a tertiary 
hospital in Oman, including its clinical presentations 
and outcomes. In addition, representative cases are 
described to highlight various manifestations of CVT 
and challenges in the management of this condition.
Methods
This retrospective study was conducted at the Sultan 
Qaboos University Hospital (SQUH), Muscat, Oman, 
between January 2009 and December 2017. All adult 
patients (>18 years old) diagnosed with CVT and 
entered into the hospital Stroke Registry were included 
in the study. Cases of cavernous sinus thrombosis were 
excluded due to their relation to infective conditions. 
In addition, patients with sinovenous disease related to 
trauma or local malignancy were also excluded. 
Electronic medical records were systematically 
reviewed to collect demographic, clinical, imaging, treat- 
ment and outcome data. A CVT diagnosis was based 
on clinical features such as headaches, seizures, altered 
sensorium and focal neurological deficits, supported 
by imaging findings typical of sinovenous thrombosis. 
All patients were investigated for possible underlying 
thromboses. Other investigations included a complete 
blood count (CBC) and coagulation profile as well as 
tests for autoimmune conditions and procoagulant 
states such as proteins C, S and antithrombin III def-
iciencies and antiphospholipid syndrome. 
This study received ethical approval from the 
Medical Research & Ethics Committee of the College of 
Medicine & Health Sciences, Sultan Qaboos University 
(MREC #1062).
Results
A total of 900 patients with cerebrovascular disease 
were treated at SQUH during the study period, of which 
30 (3%) were diagnosed with CVT. The male-to-female 
ratio was 2:3 and the mean age was 36.8 ± 11 years old. 
The mean duration of symptoms was 7.4 ± 3 days, with 28 
patients (93%) having symptoms of 1–14 days duration, 
while the remaining two patients had symptoms which 
evolved over a period of 30 and 45 days, respectively. The 
28 patients were evaluated initially by the Emergency 
Medical Services, while the two patients with a longer 
duration of symptoms were admitted to the hospital 
ward. Headache was the most common symptom (83%), 
followed by altered sensorium (50%), seizures (43%) and 
hemiparesis (33%). The initial differential diagnosis incl- 
uded status epilepticus, arterial strokes, neuroinfections, 
intracerebral haemorrhage, mass lesions and cerebral 
angiitis, in addition to CVT. Risk factors were present 
in 16 patients (53%), including pregnancy/puerperium 
(17%), systemic malignancy (13%), oral contraceptive 
use (7%), systemic lupus erythematosus (3%) and protein 
Table 1: Sociodemographic and clinical characteristics 
of cerebral venous thrombosis patients at the Sultan 
Qaboos University Hospital, Muscat, Oman (N = 30)
Characteristic n (%)






Altered sensorium 15 (50)
Seizures 13 (43)
Hemiparesis 10 (33)
Mean duration of symptoms in days ± SD 7.4 ± 3
Risk factors* 16 (53)
Pregnancy/puerperium 5 (17)
Systemic malignancy 4 (13)
Oral contraceptive use 2 (7)
SLE 1 (3)




IV mannitol 13 (43)
Anticonvulsant 11 (37)
ICU care 6 (20)
Warfarin 21 (70)
Short-term outcome
Died during hospital stay 3 (10)
Survived 27 (90)
Long-term outcome
Complete recovery 23 (77)
Neurological deficit 4 (13)
SD = standard deviation; SLE = systemic lupus erythematosus; 
LMWH = low-molecular-weight heparin; IV = intravenous; 
ICU = intensive care unit.
*Percentages do not add up to 100% as some patients may have had 
more than one risk factor, symptom or treatment. †Including one 
patient with a protein C deficiency and one patient with an anti-
thrombin III deficiency.
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C and anti-thrombin III deficiencies (7%). Despite ext- 
ensive investigations, no underlying cause could be 
established in the remaining 14 patients (47%) [Table 1]. 
Either computed tomography (CT) or magnetic 
resonance imaging (MRI) of the brain was performed 
in all 30 patients, with the majority (67%) undergoing 
both modalities. A total of 25 patients (83%) underwent 
CT scans, which were abnormal in 21 patients 
(84%). Parenchymal haemorrhage and infarcts were 
observed in 28% and 40% of patients, respectively. 
Using contrast CT venography, transverse sinus (TrS) 
thrombosis was seen in 48% of patients, superior 
sagittal sinus (SSS) thrombosis in 44%, sigmoid sinus 
(SigS) thrombosis in 32%, internal jugular vein (IJV) 
thrombosis in 16% and straight sinus (SS) and cortical 
vein thrombosis were each seen in 8% of patients. 
Empty delta sign was seen in eight patients (32%). The 
MRI scans of all patients were abnormal. Infarcts were 
the most common MRI abnormality (40%), followed by 
haemorrhage (12%). Magnetic resonance venography 
(MRV) revealed TrS thrombosis in 52% of patients, SSS 
and SigS thrombosis in 44% each, cortical vein thrombosis 
in 20% and IJV and SS thrombosis in 8% each. Empty 
delta sign was observed in five patients (20%) [Table 2].
With regards to treatment, 27 patients (90%) rec- 
eived low-molecular-weight heparin (LMWH) in therap-
eutic doses over an initial 7–14-day period. A total of 13 
patients (43%) received intravenous (IV) mannitol and 
11 (37%) received anticonvulsants. Six patients (20%) 
required intubation and ventilation in the intensive 
care unit (ICU) due to either an altered mental status 
or status epilepticus. A total of 21 patients (70%) were 
prescribed warfarin for the purposes of long-term anti- 
coagulation, adjusted to a target international normalised 
ratio (INR) of 2.3. This treatment was continued for 
periods ranging from three months for puerperal CVT 
cases to a year or longer for other conditions. Patients 
with either recurrent CVT or high-risk procoagulant 
states were advised to continue taking anticoagulation 
medications indefinitely.
 Overall, 27 patients (90%) survived. The remaining 
three patients (10%) died due to either extensive thromb- 
osis with malignant brain oedema, advanced malign-
ancy or sepsis complicating a central nervous system 
infection. One patient underwent surgical evacuation of 
a hemispheric haematoma with perioperative recogn- 
ition of the thrombosed veins; after one year, he was 
readmitted with recurrent CVT after having discont-
inued anticoagulation medications. At follow-up, 23 
patients (77%) showed complete neurological recovery. 
The following subsections highlight four different pres- 
entations of CVT seen during the study period.
puerperal cerebral venous 
thrombosis
A 23-year-old woman underwent an emergency Caes- 
arean section due to severe pre-eclampsia at 29 gestational 
weeks. She had a family history of venous thrombotic 
events with a history of deep vein thrombosis (DVT) 
on her mother’s side. Although she recovered promptly 
following the procedure, she presented 10 days later with 
a headache, left-sided weakness and recurrent generalised 
seizures progressing to status epilepticus. The seizures 
were controlled with IV phenytoin. An examination 
revealed drowsiness and left hemiparesis. 
Table 2: Imaging features of cerebral venous thrombosis 
patients at the Sultan Qaboos University Hospital, Muscat, 




Parenchymal haemorrhage 7 (28)
Non-haemorrhagic/haemorrhagic infarct 10 (40)‡
Contrast CTV 25 (83)
TrS thrombosis 12 (48)
SSS thrombosis 11 (44)
SigS thrombosis 8 (32)
IJV thrombosis 4 (16)
SS thrombosis 2 (8)
Cortical vein thrombosis 2 (8)




Non-haemorrhagic/haemorrhagic infarct 10 (40)§
MRV 25 (83)
TrS thrombosis 13 (52)
SSS thrombosis 11 (44)
SigS thrombosis 11 (44)
Cortical vein thrombosis 5 (20)
IJV thrombosis 2 (8)
SS thrombosis 2 (8)
Empty delta sign 5 (20)
CT = computed tomography; CTV = computed tomography venography; 
TrS = transverse sinus; SSS = superior sagittal sinus; SigS = sigmoid sinus; 
IJV = internal jugular vein; SS = straight sinus; MRI = magnetic resonance 
imaging; MRV = magnetic resonance venography. 
*All patients had either CT or MRI brain scans, with 20 patients (67%) 
undergoing both imaging modalities. †Percentages do not add up to 100% 
as some patients may have had more than one imaging feature. ‡Comp-
rising five patients with non-haemorrhagic infarcts and five patients with 
haemorrhagic infarcts. §Comprising three patients with non-haemorrhagic 
infarcts and seven patients with haemorrhagic infarcts.
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A CT scan of the brain revealed bifrontal mixed-
density lesions suggestive of haemorrhagic venous 
infarcts [Figure 1A]. A contrast CT scan showed evidence 
of a filling defect in the SSS and left TrS, suggestive of dural 
venous thrombosis. Extensive investigations, including 
a factor VIII assay and tests for protein C, protein S and 
anti-thrombin III deficiencies, were normal or negative. 
The patient was diagnosed with puerperal CVT and 
received a weight-based dosage of subcutaneous LMWH. 
However, an MRI scan of the brain two days later revealed 
diffuse oedema and an increase in the size of the right 
hemispheric infarction [Figure 1B]. An MRV confirmed 
thrombosis of the anterior part of the SSS and right 
TrS [Figure 1C].
After further treatment, the left hemiparesis impr- 
oved gradually. The patient was discharged on warfarin 
treatment adjusted to an INR of 2.3, which she cont-
inued taking for one year. At a one-year follow-up, she 
appeared normal. Later, she received LMWH prophy- 
lactically during two subsequent uneventful pregnancies.
recurrent cerebral venous 
thrombosis
A 60-year-old man presented with a two-day history of 
generalised severe headaches associated with vomiting 
and a generalised tonic-clonic seizure. He remained 
unresponsive after the seizure, with normal reactive 
pupils, left facial paresis and dense left-sided hemiparesis. 
There was no evidence of recent weight loss, trauma or 
alcohol abuse. The results of blood investigations,  such 
as plasma glucose, CBC, biochemistry and coagulation 
parameters, were normal. 
A CT scan of the brain performed at admission 
showed patchy right parietal haemorrhage, a streak of 
blood in the left parietal cortical region and hyper-
density along the SSS [Figure 2A]. He received IV 
levetiracetam and mannitol and was managed in the 
ICU. The altered sensorium further worsened the next 
day. An MRI scan showed an increase in the size of the 
right parietal haematoma with mass effects and a mid-
line shift [Figure 2B]. An MRV confirmed thrombosis 
of the SSS extending to the TrS, SS and further into the 
right IJV [Figure 2C]. 
The patient underwent an emergency craniotomy 
with decompression of the right parietal haematoma. 
During the surgery, thrombosis of the cortical veins was 
confirmed. He received an enoxaparin sodium injection 
as well as IV mannitol and phenytoin. Further invest-
igations for autoimmune conditions, procoagulant states 
and occult malignancies were negative. Despite the cont- 
inuation of anticoagulation treatment, his ICU stay was 
complicated by DVT leading to extensive lower limb 
oedema, requiring the placement of an inferior vena 
cava filter.
Over the next two weeks, the patient’s altered 
sensorium and left hemiplegia improved. He was advised 
to take warfarin on a long-term basis; however, he stopped 
after two years. A year later, he presented with a sudden- 
onset severe headache, disorientation and generalised 
seizures without focal deficits. Brain CT and MRI scans 
showed a left temporal haemorrhagic infarct with 
surrounding oedema due to thrombosis of the vein of 
Labbé as well as the major sinuses. He was treated with 
levetiracetam, LMWH and IV mannitol. The patient 
improved with no overt neurological deficits and good 
functional recovery. He was advised to continue taking 
warfarin indefinitely.
deep vein thrombosis
A 41-year-old woman presented to the emergency 
department with a one-day history of left-sided weakness, 
impaired speech and altered sensorium. There were no 
seizures. She reported having a history of oral contra-
ceptive use of unspecified duration. Upon presentation, 
the patient was conscious but had difficulty finding 
words. Both pupils and optic fundi appeared normal. 
 
Figure 1: Imaging of the brain of a 23-year-old woman 
with puerperal cerebral venous thrombosis showing 
(A) mixed-density bifrontal venous infarcts on computed 
tomography, (B) increased involvement of the right hemi- 
sphere two days later on magnetic resonance imaging 
and (C) thrombosis of the anterior two-thirds of the 
superior sagittal sinus (arrow) and right transverse sinus 
upon magnetic resonance venography. 
 
Figure 2: Imaging of the brain of a 60-year-old man with 
recurrent cerebral venous thrombosis showing (A) right 
parietal patchy haemorrhage, a thrombosed cortical 
vein in the left parietal region (arrow) and hyperdensity 
along the superior sagittal sinus (arrowhead) on 
computed tomography, (B) an increase in the size of 
the right parietal haematoma upon magnetic resonance 
imaging the next day and (C) thrombosis of the superior 
sagittal sinus extending to the transverse and sigmoid 
sinuses and further into the right internal jugular vein 
(arrow) upon magnetic resonance venography.
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She had left hypotonic hemiplegia but normal power on 
the right side. Her tendon reflexes were brisk and she 
had bilateral extensor plantar responses. Blood invest-
igations revealed a haemoglobin level of 15.2 g/dL with 
mild neutrophilic leukocytosis and a C-reactive protein 
level of 22 mg/dL. The results of biochemistry tests were 
normal. 
One day after the onset of symptoms, a brain CT 
scan showed mild diffuse oedema without acute infarcts 
or haemorrhage. However, the SSS was prominent and 
hyperintense, suggesting sinus thrombosis, with suspected 
cortical vein thrombosis in the left frontal and parietal 
regions [Figure 3A]. Therapeutic doses of LMWH were 
administered. However, the altered sensorium worsened 
the next day. The patient was drowsy and only opened 
her eyes in reaction to pain. An MRI of the brain showed 
bilateral parasagittal and frontoparietal hyperintensities 
as well as symmetrical hyperintensities in the basal 
ganglia and thalamus, typical of CVT involving the deep 
venous system [Figures 3B and C]. An MRV showed 
extensive thrombosis of the SSS and left TrS, SigS, 
bilateral parasagittal cortical veins as well as of the deep 
venous system [Figure 3D]. 
The patient received IV mannitol and a levetiracetam 
injection along with LMWH. A work-up for antinuclear 
antibodies (ANAs), antiphospholipid antibodies and 
thrombophilia was negative. Gradually, the patient’s 
speech and motor functions improved with time. Event- 
ually, the LMWH anticoagulant treatment was replaced 
with warfarin at a target INR of 2–3. At discharge, she 
was ambulant with no focal neurological deficits.
raised intracranial pressure
A 21-year-old man was admitted with a severe general- 
ised headache of six days’ duration, recurrent vomiting 
and double vision. He did not report any focal weakness, 
seizures or loss of consciousness. Upon examination, 
the patient was alert, with restricted abduction of the 
right eye and bilateral florid papilloedema, suggestive 
of raised ICP. At admission, a brain CT scan revealed no 
parenchymal changes; however, there was evidence of 
thrombosis of the SSS and TrS and empty delta sign 
[Figures 4A and B]. Additionally, MRI scans showed 
normal brain parenchyma as well as extensive thrombosis 
involving the SSS and TrS [Figures 4C and D].
The patient’s haemoglobin level was 17.9 g/dL and 
his haematocrit percentage was 49%, consistent with a 
diagnosis of polycythaemia. However, his ANAs and 
antiphospholipid antibodies were normal and tests for 
C- protein, S-protein and antithrombin III deficiencies 
and the janus kinase 2 mutation were negative. No 
specific cause for the polycythaemia could be determined. 
The patient was treated with IV tramadol and subcut- 
aneous LMWH. Repeated venesections were performed 
 
Figure 3: Imaging of the brain of a 41-year-old woman 
with deep cerebral venous thrombosis showing (A) 
thrombosis of the superior sagittal sinus (SSS) as well 
as the left frontal and parietal cortical veins (arrows) on 
computed tomography, (B) biconvex hyperintensities 
in the thalamus-basal ganglionic region (arrow) as well 
as (C) cortical venous infarcts (arrow) upon magnetic 
resonance imaging the next day and (D) the absence of 
flow void in the deep venous system as well as the SSS 
(arrowheads) upon magnetic resonance venography.
 
Figure 4: Imaging of the brain of a 21-year-old man with 
thrombosis restricted to the major dural venous sinuses 
showing (A) empty delta sign in the superior sagittal 
sinus (SSS) with surrounding contrast (arrow) and (B) 
thrombosis of the transverse sinus (TrS) (arrow) on 
computed tomography, (C) normal parenchyma upon 
magnetic resonance imaging and (D) thrombosis of 
the SSS and TrS upon magnetic resonance venography 
(arrowhead).
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to reduce his haematocrit percentage. One week later, 
the patient reported that his headache had improved 
remarkably. The papilloedema and sixth cranial nerve 
palsy improved gradually. He was discharged with a 
prescription for warfarin. 
Discussion 
This study explores patterns of CVT presentation, diagn- 
osis and outcomes among patients at a tertiary hospital 
in Oman. Despite the small number of cases, the majority 
of patients resembled previously reported series in most 
respects, such as onset in young adulthood, a female 
predominance, the rapid evolution of symptoms over 
a few days, a relatively low mortality rate and complete 
improvement among most survivors.1,3,4 
As illustrated in the four representative cases 
described, CVT may present in certain recognisable 
syndromes which often correlate with patterns of cerebral 
vein or dural sinus involvement.4–7 Such presentations 
may include raised ICP/space-occupying lesion, acute 
stroke-like presentations, status epilepticus/seizures, 
diffuse encephalopathy, comas and, rarely, a posterior 
fossa syndrome. The first case had puerperal CVT, the 
most common form of CVT in developing countries.4,8 
Despite its monomorphic clinical profile, no specific 
cause for puerperal CVT is yet recognised.8 The second 
and third cases illustrate the rapid evolution of CVT 
symptoms. The overall risk of relapse in CVT cases 
is 6.5%, decreasing to 3% for patients with puerperal 
CVT.9,10 Recurrent CVT generally occurs more often 
among males, such as in the second case.6 In the third 
case, the patient developed CVT due to oral contra-
ceptive use. This progressed to encephalopathy and 
altered sensorium and pyramidal signs signifying dien- 
cephalic dysfunction due to deep CVT. Other manif-
estations of deep venous system involvement include 
ophthalmoparesis, ptosis, decerebrate posturing, coma 
and movement disorders reflecting the regions drained 
by the affected veins. The fourth patient had isolated 
major dural sinus thrombosis without parenchymal 
changes, with symptoms of headache, papilloedema and 
sixth cranial nerve palsy; the latter is a classic example of 
a false localising sign.
Every patient with CVT should be investigated for 
an underlying cause or risk factor.11 Ovarian hormonal 
changes related to the puerperium, oral contraceptive 
use, haematological disorders, prothrombotic states and 
malignancy constitute common risk factors. In the 
context of pregnancy or soon after labour, changes in 
the coagulation cascade may play a role in CVT devel- 
opment; anaemia and dehydration may also be influ-
encing factors, although puerperal CVT has not been 
associated with any specific procoagulant risk factor.4,8 
The presence of certain risk factors may influence the 
duration of anticoagulation treatment. However, in most 
CVT series, there is no underlying cause or predisposing 
condition. 
Ideally, MRI plus MRV is the preferred imaging 
approach to confirm a diagnosis of CVT.9,12,13 However, 
a cranial CT scan is often the initial investigation perf- 
ormed in emergency cases and can provide several indic- 
ations of the correct diagnosis. Changes involving the 
venous structures as well as parenchymal changes may 
be seen on CT brain scans. Cord sign, dense triangle 
sign and empty delta sign are well-known direct signs 
of CVT.9,12,13 Cord sign appears as a linear hyperdensity 
on a non-contrast scan, usually on the cortical surface 
due to thrombosis of the cortical veins. A thrombus in 
the SS or vein of Galen may be similarly visualised.9,12,13 
A dense triangle sign on a non-contrast CT scan is 
typically seen along the thrombosed SSS. On contrast-
enhanced CT scans, an empty delta sign—wherein 
the contrast flows around a central and relatively 
hypodense thrombus—can be observed in the dural 
venous sinus region in up to 60% of CVT cases.7 
Indirect signs of CVT on CT occur due to the effects of 
venous or sinus thrombosis on the brain parenchyma. 
Although common, the specificity of such signs is 
low; thus, they may not be sufficient for a definitive 
diagnosis of CVT. Multiple non-haemorrhagic infarcts 
not conforming to an arterial territory or multifocal 
or confluent areas of haemorrhage are suggestive of 
CVT. Extensive brain oedema, compressed ventricles 
or bihemispheric hypodensities may be caused by 
thrombosis of the major sinuses or cortical veins; these 
features are seen in 25–42% of CVT cases.12 Deep CVT 
gives rise to fairly typical biconvex diencephalic hypo-
densities with cord sign in the internal cerebral veins 
or SS.14,15
When used together, MRI and magnetic resonance 
angiography (MRA) have a high degree of sensitivity and 
specificity in the diagnosis of CVT.12 A gyriform pattern 
of venous infarcts, thrombosed cortical veins or venous 
sinuses, different temporal stages of haemorrhagic 
infarcts or haematomas and associated brain oedema 
may be observed. Acute parenchymal haemorrhage 
as well as thrombi located within the dural sinuses 
may vary in appearance over time, appearing isointense 
on T1 and T2 sequences in the first few days (due to the 
predominance of deoxyhaemoglobin in the clot), then 
hyperintense between days 5–15 (due to the formation of 
methaemoglobin), before becoming isointense again.6 
MRV has the advantage of depicting most of the cerebral 
venous system noninvasively. Thrombosis most comm- 
only affects the SSS (62%) and TrS (41%), while the 
SS (18%), deep venous system (11%) and IJV (12%) are 
less frequently involved.16 Two direct signs of CVT 
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on MRA images are the absence of high flow in the 
dural sinus region which is not hypo- or aplastic and 
a ‘frayed’ flow signal in the sinus region after partial 
recanalisation. Dilated collateral medullary veins and 
prominent emissary veins crossing the skull may also 
be observed in later stages.4 Conventional angiography, 
preferably digital subtraction angiography, is useful in 
patients with equivocal signs on other modes of imaging.
The management of CVT has evolved significantly 
in the last few decades.2 Prompt diagnosis and treatment 
have been shown to drastically reduce mortality and 
improve outcomes, even in the presence of intracer-
ebral haemorrhage, as in the first case described in the 
current study.4 Anticoagulation treatment, typically with 
LMWH, is the standard of care, despite limited evidence 
to support its use.11,13,17,18 Weight-based dosing for anti- 
coagulants significantly improves outcomes and reduces 
mortality, even among patients with haemorrhagic 
infarcts or haematomas.11,13,17,18 Overall, LMWH may 
be safer than unfractionated heparin, although the latter 
may be preferable perioperatively.17 Patients should be 
monitored closely for evidence of haemorrhage or 
heparin-induced thrombocytopaenia. 
Anticerebral oedema measures such as mannitol, 
hypertonic saline or hyperventilation may be required 
for the emergent control of raised ICP, particularly for 
patients with extensive infarctions involving the major 
dural sinuses; however, the benefits of these measures 
have not yet been systematically evaluated.18,20 Anti-
convulsants are clearly indicated among patients with 
seizures; moreover, due to the high incidence of seizures 
in CVT (35–50%), some researchers recommend 
prescribing these prophylactically.5,11,19 Steroids and 
acetazolamide are not beneficial in CVT treatment.9
Novel approaches such as surgical decompression 
and intrasinus thrombolysis or thrombectomies have 
been explored in select cases of CVT.11,18 Patients with 
lateral or focal brain oedema due to infarction/haem-
orrhage or thrombosed veins causing mass effects and 
impending herniation should be considered in a timely 
manner for an emergency decompressive craniectomy. 
Such surgical interventions may require the transient 
interruption of anticoagulation measures. In a previous 
series of 56 CVT patients with large infarcts causing 
significant mass effects, decompressive craniectomies 
resulted in good outcomes in 54% of cases.20 However, 
25% of the patients died. Poor outcomes were associated 
with coma at admission, advanced age, a need for vent-
ilation and severe neurological deficits.20 Other studies 
have reported better mortality and functional recovery 
rates following surgical intervention.21,22
Endovascular interventions such as thrombolysis 
or a thrombectomy have been utilised in thrombosis 
mainly involving the major dural venous sinuses causing 
raised ICP and not improving following an initial anti- 
coagulation trial.20–26 An endovascular catheter is placed 
inside the clot to deliver an infusion of actilyse for 
thrombolysis or a mechanical clot-retrieving instrument 
may be used for mechanical throbectomy.25 A multi-
centre randomised clinical trial was initiated in 2013 
to compare the effectiveness of endovascular thromb-
ectomy in comparison with anticoagulant therapy; 
unfortunately, it was prematurely terminated in 2016.25 
A retrospective study found that the intrasinus infusion 
of a thrombolytic agent with mechanical thrombectomy 
in 29 patients with dural sinus thrombosis resulted in 
similar 90-day outcomes to those of 37 patients treated 
with anticoagulants alone.26
Long-term anticoagulation treatment, usually 
involving warfarin titrated to an INR of 2–3, is 
recommended to prevent recurrent venous thrombosis 
as well as other complications such as a pulmonary 
embolism.9,13 However, due to a lack of randomised 
trials, recommendations for long-term anticoagulation 
are mostly based on expert consensus. In puerperal or 
oral contraceptive-associated CVT, anticoagulants are 
recommended for 12 weeks after an initial course of 
heparin; thereafter, subcutaneous LMWH is recomm- 
ended during subsequent pregnancies to prevent 
recurrence.27 Patients with CVT provoked by specific 
triggers (e.g. infections, medication or catheter placement) 
or those with no risk factors for possible recurrence 
should be treated with anticoagulants for 6–12 months. 
In contrast, oral anticoagulants are continued indefinitely 
among patients with recurrent CVT or those with 
severe prothrombotic states such as antiphospholipid 
syndrome or genetic thrombophilias. While newer oral 
anticoagulants have been studied, there is currently 
insufficient evidence to recommend their use.28
In recent decades, the overall prognosis for patients 
with CVT has improved, likely due to early anticoag-
ulation measures and improvements in the quality of 
critical care.2,4,29 Although CVT is three times more 
common among women, the prognosis is worse for men.3 
Additionally, CVT cases related to pregnancy/puer-
perium or hormonal changes have a much better 
prognosis than those associated with thrombophilia 
or internal malignancy.8,27 Furthermore, those who 
improve after acute CVT episodes often recover with 
very few neurological deficits in contrast to arterial 
stroke cases. However, death or a state of dependency 
occurs in about 15% of CVT cases.21 Of all CVT 
syndromes, DVT has the highest mortality rate.5,6,15 
Conclusion
Although an uncommon condition, the prompt diagn-
osis and treatment of CVT can prevent serious and 
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potentially fatal outcomes. This study illustrates the 
varied manifestations of CVT at a tertiary hospital in 
Oman and highlights the usefulness of prompt imaging 
to ensure a timely diagnosis. Effective anticoagulation 
measures ensured good outcomes among the survivors, 
despite severe neurological deficits at presentation.
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